Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab vs Triamcinolone Acetonide in Gouty Arthritis Patients with CKD
NCT01593527Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2012
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of canakinumab in gouty arthritis, sponsored by Novartis. Planned start Sep 2012; status: withdrawn.
02
Drugs
canakinumab
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT01593527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593527.